



Pandemic Security Initiative

A CELDARA MEDICAL INITIATIVE



The Issue

Pandemics are a clear and present danger to life as we know it. They are existential, they have plagued us for thousands of years, and we still do not have a solution. We remain structurally unprepared to combat infectious disease.

- There is no market for diseases without incidence. The standard drug development model doesn't work for most infectious diseases — especially sporadic ones.
- Without a market to provide returns, there is no investment. Pandemic threat mitigation is almost exclusively a governmental undertaking.

The Solution: Pandemic Security Initiative, a Public-Private Partnership

Unleash American innovation already present in our universities, government labs, and small businesses to prepare and protect the country from future infectious disease pandemics.

- NIAID is the world's premiere funding source for infectious diseases, providing almost \$6B/y to the best and brightest infectious disease researchers in the country. They are constantly inventing and discovering. They are not, however, equipped to turn an invention into a therapy.
- An entrepreneurial, agile, executive and purpose-built public-private partnership (PPP) with a sharp focus on identifying and developing novel diagnostics, vaccines, prophylactics, and therapeutics would protect the country against pandemic-scale threats.
- **As an entrepreneurial, operating, drug-developing entity**, this PPP is complementary to the funding and prioritization activities of BARDA and HHS.
- With development funding from the federal government, pricing of approved innovative medicines will be limited to "cost-plus" (based on CoGS, not development costs).

FAST FACT: INVESTING IN THE U.S. WORKFORCE

The public private partnership is also an investment in American workers. All research, development, and manufacturing will take place in the U.S.

MISSION

Prepare and protect the nation from future infectious disease threats.

VISION

Deliver an arsenal of tests, vaccines, and medicines to secure the nation's health and economy.

Celdara is Uniquely Positioned to Lead

Celdara Medical was built to transform academic innovations into high-impact medicines. In concert with Celdara affiliates Virtici (Seattle) and MBV (Indianapolis), Celdara already works with hundreds of academic institutions representing well over \$10B/year in NIH research funding.

Celdara Medical created the Pandemic Security Initiative, which has access to a unique innovation pipeline that spans the United States and beyond. The initiative seeks to unleash existing innovation in American universities, government labs and small and large businesses. Celdara has ongoing relationships with most research universities and institutions across the country, in addition to the CDMOs who manufacture, the CROs who run clinical trials, and the pharma and biotech companies who provide unique technical and market insights.

Celdara is the fastest-growing company in the state of New Hampshire (in all sectors, based on 3-year AAGR) for each of the last three years, and has been in the top 10 for each of the last six years, winning accolades from the NIH, SBA, and various federal, state, and local agencies, as well as national and international publications. Celdara has established academic innovation networks worldwide, and "boots on the ground" in Boston, New York, Indianapolis (MBV), and Seattle (Virtici).

Furthermore, Celdara has — with the support of the NIH — established multi-state partnerships to improve medical entrepreneurship in Vermont, New Hampshire, Maine, Rhode Island, and Delaware. Our affiliate Virtici leads a similar effort for Alaska, Hawaii, Idaho, Montana, Nevada, New Mexico, and Wyoming. Universities, pharmaceutical companies, CROs, and CDMOs have been **overwhelmingly supportive** of the Pandemic Security Initiative.

The PPP provides financial security for the developer, and pricing security for our government, while creating jobs, securing supply chains, and securing the health and economy for the benefit of all.


Bridging the Gap: Unleashing Innovation for Patient & Societal Benefit

Existential threats require layers of protection. The Pandemic Security Initiative is a potent, additive layer of security, built on strong and productive foundations.

Scientific funding, research, and innovation processes already work exceptionally well. However, there is a gap between the **invention** of new tests, vaccines, and therapies, and our ability to develop and **stockpile** them. The Pandemic Security Initiative proactively identifies the most promising medical countermeasure innovations, and develops them into approved products, spanning the gap to provide our clinicians and first responders with innovative new medicines and tests.

Today, innovation thrives with the support of government-funded research.

However, much of this innovation doesn't reach patients because there is no commercial market for diseases without incidence. Without a market, there is no investment incentive, resulting in a gap in the normal drug development process. Standard push and pull incentives have not sufficiently filled this gap.



Celdara is bridging the gap, building a public-private partnership (PPP) to develop and unleash a pipeline of innovation that is already present in our universities, government labs, and small businesses to protect the country against pandemic-scale threats.

Our Partners

Celdara Medical's academic and research institution partners span America and beyond and include:

Representative Universities

- Albert Einstein College of Medicine
- Brown University
- Cedars-Sinai Medical Center
- Cincinnati Children's Hospital
- Columbia University
- Dartmouth College
- Emory University
- Florida State University
- Harvard Medical School
- Indiana University
- Johns Hopkins University
- Maine Medical Center
- Mt. Sinai School of Medicine
- North Carolina State University
- Northwestern University
- The Rockefeller University
- University of Chicago
- University of Delaware
- University of Hawaii
- University of Idaho
- University of Louisville
- University of Montana
- University of Nevada Las Vegas
- University of New Mexico
- University of Pittsburgh
- University of Washington
- University of Wisconsin
- Vanderbilt University

Representative Research Institutions

- Brigham and Women's Hospital
- Fred Hutchinson Cancer Research Center
- La Jolla Institute for Immunology
- Massachusetts General Hospital
- Mayo Clinic
- U.S. Army Medical Research Institute of Infectious Diseases